文献速递心力衰竭与心肌病

靶向经心内膜间充质前体细胞治疗心力衰竭的随机试验

Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

本研究为随机双盲多中心试验,纳入565例高危射血分数降低的心力衰竭(HFrEF)患者,比较单次经心内膜注射间充质前体细胞(MPCs)与假手术对照的疗效与安全性。主要终点(复发性失代偿HFrEF或成功复苏的症状性室性心律失常事件时间)两组相似(HR 1.17,95%CI 0.81-1.69,P=0.41)。MPCs组左心室射血分数从基线至12个月改善,在炎症患者中更明显;分析人群(n=537)中心肌梗死或卒中风险降低58%(HR 0.42,95%CI 0.23-0.76),3点主要不良心血管事件风险降低28%(HR 0.72,95%CI 0.51-1.03);炎症患者(基线高敏C反应蛋白≥2 mg/L)中分别降低75%(HR 0.25,95%CI 0.09-0.66)和38%(HR 0.62,95%CI 0.39-1.00)。

要点

  • 主要终点及次要终点均为阴性,MPCs未显著减少复发性心衰事件。
  • MPCs改善12个月左心室射血分数,炎症患者中更明显。
  • 探索性分析提示MPCs可能降低心梗/卒中及MACE风险,炎症患者中信号更强。

核心结论

  • 试验主要终点和次要终点均为阴性,预设及事后探索性分析提示MPCs可能改善结局,尤其在炎症患者中。

研究设计与样本

  • 随机、双盲、多中心研究,评估单次经心内膜注射MPCs或假手术对照,纳入565例接受指南导向药物治疗的HFrEF意向治疗患者。

主要发现

  • 主要终点两组相似(HR 1.17;95%CI 0.81-1.69;P=0.41),终末心脏事件及次要终点亦无差异。
  • 与对照相比,MPCs提高左心室射血分数从基线至12个月,尤其在炎症患者中。
  • 分析人群(n=537)中,MPCs降低心肌梗死或卒中风险58%(HR 0.42;95%CI 0.23-0.76),降低3点MACE风险28%(HR 0.72;95%CI 0.51-1.03)。
  • 炎症患者(基线高敏C反应蛋白≥2 mg/L)中,MPCs降低心肌梗死或卒中风险75%(HR 0.25;95%CI 0.09-0.66),降低3点MACE风险38%(HR 0.62;95%CI 0.39-1.00)。

关键数值与推荐

  • 主要终点为复发性失代偿HFrEF或成功复苏的症状性室性心律失常事件时间。
  • 炎症定义为基线高敏C反应蛋白≥2 mg/L。
  • 分层次要终点包括主要终点组分、首次终末心脏事件时间及全因死亡。

临床怎么用

  • MPCs不宜作为HFrEF常规治疗,主要终点未获阳性结果。
  • 对合并炎症(hs-CRP≥2 mg/L)的HFrEF患者,MPCs可能带来额外心血管获益,但需进一步验证。

局限性

  • 主要终点阴性,阳性信号来自预设及事后探索性分析,需谨慎解读。
  • 炎症亚组分析样本量较小,结果可能受混杂因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mesenchymal precursor cells (MPCs) are allogeneic, immunoselected cells with anti-inflammatory properties that could improve outcomes in heart failure with reduced ejection fraction (HFrEF). OBJECTIVES: This study assessed the efficacy and safety of MPCs in patients with high-risk HFrEF. METHODS: This randomized, double-blind, multicenter study evaluated a single transendocardial administration procedure of MPCs or sham-control in 565 intention-to-treat patients with HFrEF on guideline-directed therapies. The primary endpoint was time-to-recurrent events caused by decompensated HFrEF or successfully resuscitated symptomatic ventricular arrhythmias. Hierarchical secondary endpoints included components of the primary endpoint, time-to-first terminal cardiac events, and all-cause death. Separate and composite major adverse cardiovascular events analyses were performed for myocardial infarction or stroke or cardiovascular death. Baseline and 12-month echocardiography was performed. Baseline plasma high-sensitivity C-reactive protein levels were evaluated for disease severity. RESULTS: The primary endpoint was similar between treatment groups (HR: 1.17; 95% CI: 0.81-1.69; P = 0.41) as were terminal cardiac events and secondary endpoints. Compared with control subjects, MPCs increased left ventricular ejection fraction from baseline to 12 months, especially in patients with inflammation. MPCs decreased the risk of myocardial infarction or stroke by 58% (HR: 0.42; 95% CI: 0.23-0.76) and the risk of 3-point major adverse cardiovascular events by 28% (HR: 0.72; 95% CI: 0.51-1.03) in the analysis population (n = 537), and by 75% (HR: 0.25; 95% CI: 0.09-0.66) and 38% (HR: 0.62; 95% CI: 0.39-1.00), respectively, in patients with inflammation (baseline high-sensitivity C-reactive protein ≥2 mg/L). CONCLUSIONS: The primary and secondary endpoints of the trial were negative. Positive signals in prespecified, and post hoc exploratory analyses suggest MPCs may improve outcomes, especially in patients with inflammation.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Perin EC, Borow KM, Henry TD, et al. Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure. J Am Coll Cardiol. 2023. PMID: 36858705. doi:10.1016/j.jacc.2022.11.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。